Thank you, Laura
The key question is whether non-diabetic patients experience hot flashes or changes in body temperature differently compared to diabetic patients
Tirzepatide is a dual-acting injectable medication that targets two hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), both of which play roles in regulating appetite and glucose metabolism
The method of administration (self-injection, oral, or topical), treatment duration, and dosage level all impact the total cost
Common Mild Side Effects Short-term redness or slight irritation at the injection site Light water retention, especially during the initial weeks Increased appetite Mild headaches (rare and usually transient) Temporary fatigue or lightheadedness immediately after injection Who Should Avoid This Therapy People with an active cancer diagnosis or history of cancer, as GH secretagogues increase cellular replication rates Pregnant or breastfeeding individuals should avoid this therapy due to insufficient safety data on its effects during these stages
it's part of a comprehensive weight management plan. Patient Demographics and Suitability Semaglutide is generally considered for individuals with a BMI of 30 or higher (obese) or a BMI of 27 or higher (overweight) who also have weight-related health conditions like type 2 diabetes or high blood pressure
